Viridian Therapeutics, Inc. (VRDN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Jin Law
Goldman Sachs Group, Inc., Research Division

All right. Good afternoon. Let’s kick off our next session. It is my pleasure to host Viridian Therapeutics. And with me, we have Steve Mahoney and Shan Wu, CEO and CBO of the company. So a lot to talk about, very, very exciting year. Very. But before we go do it, I’m going to kick it off to Steve and Shan for opening remarks.

Stephen Mahoney
CEO, President & Director

Yes. Thanks, Rich. Thanks for having us. We appreciate it. We are on the verge of commercial approval. We are — have a PDUFA date of June 30. So very short time period until we are — we expect to be on the market.

All of our regulatory interactions have been consistent and positive and give us a lot of confidence going into that PDUFA date. We are right on track with everything. So that’s exciting. We can talk about launch dynamics and that type of thing in more detail as we go. We obviously also had our top line readout from our subcutaneous studies, REVEAL-1 and REVEAL-2, both highly positive studies, both proptosis response and diplopia.

We are advancing our Q 4- and our Q 8-weekly dosing regimens with a BLA submission targeted for Q1 of ’27. So also exciting because we think that’s a potential — has a lot of potential in the TED market going forward.

We also have a TSHR program that we have guided to an IND in Q4 of this